Picton Mahoney Asset Management Boosts Regeneron Pharmaceuticals Stake

Investment firm increases holdings in biotech company by over 800,000%

Published on Mar. 6, 2026

Got story updates? Submit your updates here. ›

Picton Mahoney Asset Management significantly increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, according to a recent SEC filing. The institutional investor now owns 8,235 shares of the biopharmaceutical company's stock, up from just 1 share previously - a staggering 823,400% increase.

Why it matters

Regeneron Pharmaceuticals is a major player in the biotech industry, known for its innovative drug discovery technologies and pipeline of biologic therapies. Picton Mahoney's substantial investment in the company signals their confidence in Regeneron's future growth potential.

The details

According to the filing, Picton Mahoney Asset Management increased its holdings in Regeneron Pharmaceuticals by 823,400.0% in the third quarter, acquiring 8,234 additional shares. The firm's total position in Regeneron is now valued at $4.6 million. This dramatic increase in ownership comes as Regeneron's stock has surged in recent months, with the company reporting strong financial results and advancing its drug development programs.

  • Picton Mahoney Asset Management increased its Regeneron Pharmaceuticals stake in the 3rd quarter of 2026.
  • Regeneron Pharmaceuticals reported its latest earnings on January 30, 2026.

The players

Picton Mahoney Asset Management

An institutional investment firm that significantly boosted its stake in Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals, Inc.

A U.S. biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

What they’re saying

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

Picton Mahoney's massive increase in its Regeneron Pharmaceuticals stake underscores the investment firm's bullish outlook on the biotech company's future prospects. This move highlights the continued investor interest and confidence in Regeneron's innovative drug pipeline and market-leading position in the rapidly evolving pharmaceutical industry.